他汀类药物的经济学研究  

Economics Study of Statins

作　　者：王宇[1] 徐颖颖[1] 张相彩[1] 郑韧[1] 王怀冲[1] 王翠莲[1] 

机构地区：[1]杭州市红十字会医院药剂科,杭州310003

出　　处：《中国现代应用药学》2015年第9期1134-1138,共5页Chinese Journal of Modern Applied Pharmacy

摘　　要：目的通过对降血脂药物经济学分析,为临床选择他汀类药物提供帮助。方法对国产和进口品种的降脂药物疗效进行了总结,通过分析药物的成本-效果,制定选药方案。结果辛伐他汀在所有他汀类药物中性价比最高,其次为瑞舒伐他汀钙,然后为普伐他汀钠片,最差的为阿托伐他汀。但辛伐他汀达标时使用剂量偏大,造成不良反应较多,目前大多研究不支持辛伐他汀的降脂疗效。与进口药物相比,国产药价格优势明显。结论与其他他汀类药物相比,瑞舒伐他汀降脂疗效明确,价格相对较低,不良反应少,建议首选瑞舒伐他汀钙降脂。OBJECTIVE To analyze the cholesterol-lowering drugs economics systems analysis to provide reference for clinical rational drug use. METHODS The efficacy of lipid lowering drugs was summarized, accordance the analysis of the cost-effectiveness of the drug, the formulation of the drug selection scheme to provide the theoretical basis for the rational drug use. RESULTS Accordance with the pharmacoeconomic analysis, rosuvastatin calcium in all statin drugs effect price ratio was the highest, followed by rosuvastatin cutting atorvastatin calcium, then to pravastatin sodium tablets, the worst for atorvastatin. However, when the dosage of simvastatin was high, the adverse reactions increased, and the effect of simvastatin sodium was not supported at present. Domestic studies showed that the advantage of domestic drug price was obvious, the cost-effectiveness was better than the imported statins. CONCLUSION The study showed that the efficacy of atorvastatin and other statins is good, the price is relatively low. From the perspective of cost-effectiveness analysis, the first choice is rosuvastatin calcium.

关 键 词：降脂药物 他汀类 药物经济学 成本-效果 

分 类 号：R972.6[医药卫生—药品]